Head-To-Head Comparison: Aphria (APHA) and Its Peers
Aphria (NYSE: APHA) is one of 33 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it compare to its competitors? We will compare Aphria to similar companies based on the strength of its profitability, dividends, earnings, valuation, analyst recommendations, risk and institutional ownership.
Valuation & Earnings
This table compares Aphria and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Aphria||$179.29 million||-$12.48 million||-42.27|
|Aphria Competitors||$218.50 million||-$99.79 million||1.73|
This table compares Aphria and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and target prices for Aphria and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aphria currently has a consensus target price of $9.01, indicating a potential upside of 93.73%. As a group, “Medicinals & botanicals” companies have a potential upside of 97.53%. Given Aphria’s competitors higher probable upside, analysts plainly believe Aphria has less favorable growth aspects than its competitors.
Institutional & Insider Ownership
9.6% of Aphria shares are owned by institutional investors. Comparatively, 21.6% of shares of all “Medicinals & botanicals” companies are owned by institutional investors. 25.8% of shares of all “Medicinals & botanicals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Aphria has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, Aphria’s competitors have a beta of 2.56, meaning that their average share price is 156% more volatile than the S&P 500.
Aphria beats its competitors on 7 of the 13 factors compared.
Aphria Company Profile
Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada.
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.